Immunoprophylactic strategies used in a NHP model of acute GVHD result in a clinical picture that can be categorized as hyperacute, suppressed, or breakthrough acute GVHD. (A) Experimental schema detailing the transplant protocol and immunoprophylaxis regimens used throughout this study. (B) Clinical score based on our previously described NHP GVHD clinical scoring system.4 Colored circles represent the clinical categories of hyperacute (red), suppressed (green) and breakthrough acute (orange) disease. (C) Comparison of survival curves between hyperacute and breakthrough acute cohorts. The Kaplan-Meier product-limit method was used to calculate survival. Significance was determined using log-rank statistics. aGVHD, acute GVHD; GCSF, granulocyte colony-stimulating factor; TBI, total body irradiation.
